News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gilead Sciences Ltd. (GILD) (JOBS) Deepens Roots in Seattle, Seeks Long-Term Payoff From Lung Disease Research



1/13/2010 7:26:43 AM

Bookmark and Share

Xconomy.com -- Gilead Sciences spent $365 million to get a toehold in Seattle back in 2006, and so far, it has zero U.S. product sales to show for it. That’s made investors antsy, but it hasn’t deterred the world’s second-most valuable biotech company from continuing to bet big on Seattle as part of its plan to diversify away from its heavy reliance on HIV medications.

Read at Xconomy


comments powered by Disqus
Xconomy
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES